SATB2 Is Expressed in a Subset of Pulmonary and Thymic Neuroendocrine Tumors

Julie A. Vrana, Jennifer M. Boland, Simone B.S.P. Terra, Hao Xie, Sarah M. Jenkins, Aaron S. Mansfield, Julian R. Molina, Stephen D. Cassivi, Anja C. Roden

Research output: Contribution to journalArticlepeer-review


Objectives: To evaluate SATB2 expression and prognostic implications in a large cohort of thoracic neuroendocrine tumors. Methods: Surgical pathology files (1995-2017) and an institutional thymic epithelial tumor database (2010-2020) were searched for resected neuroendocrine tumors. Cases were stained with SATB2 (clone EP281). Percent SATB2-positive tumor cells and expression intensity were scored. Results: In the lung, SATB2 was expressed in 5% or more of tumor cells in 29 (74.4%) of 39 small cell carcinomas and 9 (22.5%) of 40 atypical and 26 (40.6%) of 64 typical carcinoid tumors. SATB2 percent tumor cell expression and intensity were higher in small cell carcinomas than in carcinoid tumors (both P<.001, respectively). After adjusting for tumor subtype, SATB2 expression did not correlate with outcome. In the thymus, four (100%) of four atypical carcinoid tumors and one large cell neuroendocrine carcinoma but no small cell carcinoma (n=2) expressed SATB2 in 5% or more of tumor cells. Conclusions: SATB2 (clone EP281) is expressed in a large subset of pulmonary and thymic neuroendocrine tumors and therefore does not appear to be a useful marker to identify the origin of neuroendocrine tumors. Validation studies are needed, specifically including thymic neuroendocrine tumors, as the expression pattern might be different in those tumors.

Original languageEnglish (US)
Pages (from-to)853-865
Number of pages13
JournalAmerican journal of clinical pathology
Issue number5
StatePublished - Nov 1 2021


  • Carcinoid tumor
  • Pulmonary
  • SATB2
  • Small cell carcinoma
  • Thymic

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Dive into the research topics of 'SATB2 Is Expressed in a Subset of Pulmonary and Thymic Neuroendocrine Tumors'. Together they form a unique fingerprint.

Cite this